LB PHARMACEUTICALS INC 8-K

What Happened
LB Pharmaceuticals Inc. filed an 8-K reporting that Chief Medical Officer Dr. Anna Eramo resigned effective June 15, 2026 and will transition to an advisor role on June 16, 2026. She will continue providing full-time consulting services to the company through September 15, 2026 under a Separation and Consulting Agreement dated June 8, 2026. The company stated the departure is for personal reasons and is not related to its clinical program operations.

Key Details

• Resignation filed June 8, 2026; separation effective June 15, 2026; consulting period runs through September 15, 2026.
• If Dr. Eramo remains engaged and complies through the consulting period, she will receive: (a) her current base salary paid monthly through June 15, 2027; (b) 100% of her 2026 target bonus on a prorated basis; and (c) acceleration so that 66,143 previously unvested option shares become vested and exercisable on September 15, 2026.
• Her existing stock options will otherwise continue to vest per the company’s equity plans; the company will reimburse COBRA premiums (subject to standard limits).
• The agreement includes confidentiality, non-disparagement, and a release of claims.

Why It Matters
This is an executive-level change affecting the company’s clinical leadership. Management says the departure is personal and does not expect a material impact on clinical development or disclosed milestones, and a search for a replacement is underway with existing clinical teams remaining in place. Investors should note the compensation and option-vesting terms (notably the accelerated vesting of 66,143 shares and salary through mid-2027) and monitor company updates about any changes to clinical program oversight or timelines.